Efficacy of ceftazidime-avibactam in the treatment of infections due to Carbapenem-resistant Enterobacteriaceae.

ABSTRACT:

Background

Carbapenem-resistant Enterobacteriaceae (CRE) represent an important global threat. The aim of this study is to describe the clinical course and outcomes of patients with CRE infections treated with ceftazidime-avibactam (CAZ-AVI) compared to patients treated with other agents.

Methods

A retrospective cohort study of patients with established CRE infections from January 2017 until August 2018 was conducted. All patients who received CAZ-AVI and all cultures with carbapenem-resistant isolates were screened. We compared patients who received CAZ-AVI for CRE infections with patients who received other agents.

Results

A total of 38 consecutive patients with CRE infections were identified. Age and baseline comorbidities were similar between the two groups. The m

SUBMITTER: Alraddadi BM 

PROVIDER: S-EPMC6724371 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature